

Title (en)

ANAVEX2-73 FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Title (de)

ANAVEX2-73 ZUR BEHANDLUNG VON MORBUS ALZHEIMER

Title (fr)

ANAVEX2-73 POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER

Publication

EP 3638225 A1 20200422 (EN)

Application

EP 17734901 A 20170614

Priority

US 2017037436 W 20170614

Abstract (en)

[origin: WO2018231216A1] Composition and method for treatment of Alzheimer's disease that includes ANAVEX2-73. Method of treatment of Alzheimer's disease using pharmaceutical compositions comprising ANAVEX2-73 according to an intermittent dosage regimen.

IPC 8 full level

A61K 31/341 (2006.01); **A61K 31/13** (2006.01); **A61K 31/27** (2006.01); **A61K 31/445** (2006.01); **A61K 31/55** (2006.01); **A61K 45/06** (2006.01); **A61P 25/28** (2006.01)

CPC (source: EP)

A61K 31/13 (2013.01); **A61K 31/27** (2013.01); **A61K 31/341** (2013.01); **A61K 31/445** (2013.01); **A61K 31/55** (2013.01); **A61K 45/06** (2013.01); **A61P 25/28** (2018.01)

C-Set (source: EP)

1. **A61K 31/341 + A61K 2300/00**
2. **A61K 31/445 + A61K 2300/00**
3. **A61K 31/55 + A61K 2300/00**
4. **A61K 31/27 + A61K 2300/00**
5. **A61K 31/13 + A61K 2300/00**

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2018231216 A1 20181220; AU 2017418247 A1 20200123; AU 2017418247 B2 20231214; AU 2024201661 A1 20240404; CA 3010480 A1 20181214; CN 111315375 A 20200619; EP 3638225 A1 20200422; JP 2020523417 A 20200806; JP 2022050553 A 20220330; JP 2023164615 A 20231110

DOCDB simple family (application)

US 2017037436 W 20170614; AU 2017418247 A 20170614; AU 2024201661 A 20240314; CA 3010480 A 20170614; CN 201780093392 A 20170614; EP 17734901 A 20170614; JP 2020519659 A 20170614; JP 2022001498 A 20220107; JP 2023151737 A 20230919